期刊
ACS BIOMATERIALS SCIENCE & ENGINEERING
卷 1, 期 4, 页码 183-200出版社
AMER CHEMICAL SOC
DOI: 10.1021/ab500038y
关键词
osteochondral tissue engineering; layered scaffold; biomimetic; interface engineering; clinical trial; pluripotent stem cells
资金
- Portuguese Foundation for Science and Technology (FCT) through projects TISSUE2TISSUE [PTDC/CTM/105703/2008]
- OsteoCart [PTDC/CTM-BPC/115977/2009]
- European Union's Seventh Framework Programme (FP7) [REGPOT-CT2012-316331-POLARIS]
- FCT [SFRH/BD/64717/2009]
- Investigator FCT program [IF/00423/2012, IF/00411/2013]
- Fundação para a Ciência e a Tecnologia [PTDC/CTM/105703/2008, PTDC/CTM-BPC/115977/2009, SFRH/BD/64717/2009] Funding Source: FCT
In the past few years, great progress has been made to validate tissue engineering strategies in preclinical studies and clinical trials on the regeneration of osteochondral defects. In the preclinical studies, one of the dominant strategies comprises the development of biomimetic/bioactive scaffolds, which are used alone or incorporated with growth factors and/or stem cells. Many new trends are emerging for modulation of stem cell fate toward osteogenic and chondrogenic differentiations, but bone/cartilage interface regeneration and physical stimulus have been showing great promise. Besides the matrix-associated autologous chondrocyte implantation (MACI) procedure, the matrix-associated stem cell implantation (MASI) and layered scaffolds in acellular or cellular strategy are also applied in clinic. This review outlines the progresses at preclinical and clinical levels, and identifies the new challenges in osteochondral tissue engineering. Future perspectives are provided, e.g., the applications of extracellular matrix-like biomaterials, computer-aided design/manufacture of osteochondral implant, and reprogrammed cells for osteochondral regeneration.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据